Cannabis Triumphs Where Pain Meds Failed: A Case Study In Fabry Disease

Zinger Key Points
  • A 29-year-old Fabry patient finds relief with a specific cannabis blend, reducing excruciating pain within a month.
  • Medical cannabis offers hope for Fabry disease patients with severe neuropathic pain, outperforming traditional treatments.

A recent case study highlighted the potential of medical cannabis in providing relief for neuropathic pain in a patient with Fabry disease, a genetic disorder characterized by severe, often treatment-resistant nerve pain. This development points to new avenues in pain management for those affected by this challenging condition.

Challenges In Traditional Fabry Pain Treatments

As explained in Fabry Disease News, this condition results from mutations in the GLA gene, leading to the accumulation of a molecule called globotriaosylceramide (Gb-3) in cells. This accumulation causes organ damage and significant nerve pain.

Traditional treatments, including enzyme replacement therapy, often fall short in alleviating this pain, which affects a substantial portion of Fabry patients.

Cannabis' Remarkable Results. New Hope?

The study, published in the journal Molecular Genetics and Metabolism Reports, centers on a 29-year-old male patient with Fabry disease. From childhood, he experienced intense burning pain in his hands and feet, worsened by physical exercise or fever, along with other symptoms indicative of Fabry. Despite undergoing enzyme replacement therapy and trying various medications, his neuropathic pain persisted.

The turning point came when the patient, at age 32, was referred to a pain management specialist and prescribed oral medical cannabis, comprising 12% cannabidiol (CBD) and 8% tetrahydrocannabinol (THC).

Within just a month, he reported a significant reduction in pain, especially nocturnal pain, without notable side effects. This improvement in his condition was maintained for over a year.

Rising Role Of Cannabis Treating Pain

The study’s authors say that more research is needed to establish the efficacy and safety of cannabis as a pain management tool for Fabry disease. However, they suggest that medical cannabis could be considered as a treatment option, particularly for nocturnal pain relief, when other pharmacological approaches have failed.

After decades of denying or disregarding its therapeutic properties, cannabis continues to emerge as a potential solution for various medical conditions. Its application in genetic disorders like Fabry disease is welcome news to many who suffer from chronic pain.

Read more at Fabry Disease News.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechCannabisNewsHealth CareMarketsFabry diseaseMolecular Genetics and Metabolism Reports
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...